Resistance of myeloma to lenalidomide is an emerging clinical problem, and though it has been associated in part with activation of Wnt/b-catenin signaling, the mediators of this phenotype remained undefined. Lenalidomide-resistant models were found to overexpress the hyaluronan (HA)-binding protein CD44, a downstream Wnt/b-catenin transcriptional target. Consistent with a role of CD44 in cell adhesion-mediated drug resistance (CAM-DR), lenalidomide-resistant myeloma cells were more adhesive to bone marrow stroma and HA-coated plates. Blockade of CD44 with monoclonal antibodies, free HA or CD44 knockdown reduced adhesion and sensitized to lenalidomide. Wnt/b-catenin suppression by FH535 enhanced the activity of lenalidomide, as did interleukin-6 neutralization with siltuximab. Notably, all-trans retinoic acid (ATRA) downregulated total b-catenin, cell-surface and total CD44, reduced adhesion of lenalidomide-resistant myeloma cells and enhanced the activity of lenalidomide in a lenalidomide-resistant in vivo murine xenograft model. Finally, ATRA sensitized primary myeloma samples from patients that had relapsed and/or refractory disease after lenalidomide therapy to this immunomodulatory agent ex vivo. Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.
INTRODUCTION
Lenalidomide belongs to a class of immunomodulatory agents that is increasingly used in the frontline, relapsed/refractory and maintenance settings for multiple myeloma.
1,2 Despite its broad effectiveness as a single agent, and in a number of combination regimens, the vast majority of patients eventually develop disease that demonstrates clinical lenalidomide resistance. Previously published studies from our group demonstrated that Wnt/b-catenin signaling was activated in plasma cells following acute or chronic exposure to lenalidomide. 3 However, these studies did not identify downstream mediators of the resistant phenotype, and did not validate approaches that could be translated to the clinic to overcome resistance.
One molecule of interest we considered as a potential mediator of resistance was CD44, a known b-catenin transcriptional target, 4 which is a functional component of cell adhesion-mediated drug resistance (CAM-DR). 5 A role for CD44 as a mediator of CAM-DR has been described in several cancers, [6] [7] [8] and it may in part mediate dexamethasone resistance in myeloma. 9 CD44 is a singlepass, glycosylated class-I transmembrane protein involved in multiple cellular functions, including interaction with the matrix microenvironment and intracellular signaling. 5 The extracellular portion of CD44 primarily binds to the glycosaminoglycan hyaluronan (HA), thereby contributing to cell adhesion, migration, angiogenesis, inflammation, wound healing and downstream signaling that promotes cell growth and survival. 5 An extracellular domain of CD44 can be cleaved and found as a soluble entity in the serum, where it has been identified as a biomarker correlating with poor outcomes in solid tumors such as the colon, 10 as well as hematological malignancies such as non-Hodgkin lymphoma, 11 and possibly myeloma. 12 Finally, serum HA itself may be a predictive marker of a poor prognosis for multiple myeloma. 13 These factors led us to consider the hypothesis that CD44 could be one mediator of the lenalidomideresistant phenotype in myeloma, and that its targeting could lead to lenalidomide sensitization, and possibly overcome resistance.
In the current studies, we show that models of Wnt/b-catenindependent lenalidomide-resistant myeloma demonstrated enhanced CD44 expression. This resulted in an increase in adhesive properties to stroma and HA, whereas CD44 blockade, or short hairpin RNA (shRNA)-mediated suppression, enhanced the anti-proliferative effects of lenalidomide. Sensitivity to lenalidomide in drug-naive models, and activity of lenalidomide against drug-resistant models, was enhanced using clinically relevant agents that have an impact on CD44, such as all-trans retinoic acid (ATRA). Finally, the combination of ATRA with lenalidomide enhanced activity against primary plasma cells, including from patients with lenalidomide-resistant disease, and showed anti-tumor efficacy in an in vivo model. These data support the translation of ATRA or anti-CD44 antibodies to the clinic with lenalidomide as a rational strategy to overcome lenalidomide resistance.
MATERIALS AND METHODS

Cell lines and primary samples
Drug-naïve and lenalidomide-resistant myeloma cell lines were maintained as described previously. 3 Cell line authentication was performed by our Cell Line Characterization Core using short tandem repeat profiling. Lenalidomide was removed from culture for at least seven days prior to all experiments, unless indicated otherwise. Primary plasma cells were purified from bone marrow aspirates collected from patients under an approved protocol from the Institutional Review Board at the University of Texas M. D. Anderson Cancer Center after informed consent was obtained in compliance with the Declaration of Helsinki.
Viability assays
Proliferation and viability assays with lenalidomide (Selleck Chemicals, Houston, TX, USA), IM9 CD44-blocking agent (Abcam, Cambridge, MA, USA), humanized monoclonal anti-CD44 (RO5429083, Roche Diagnostics GmbH, Penzberg, Germany) and anti-interleukin (IL)-6 antibodies (Siltuximab; Janssen Biotech, Inc., Horshma, PA, USA), FH535 (SigmaAldrich, St Louis, MO, USA) or ATRA (Sigma-Aldrich) were performed as described. 3 Briefly, cell lines or primary samples were treated with either the indicated compound or antibody for a minimum of 72 h unless otherwise indicated, followed by the addition of WST-1, and colorimetric detection of metabolic activity on a Perkin Elmer Victor 3 V plate reader (Waltham, MA, USA). Data were then normalized to vehicle controls, which were arbitrarily set at 100% viability. All data points are represented as the mean with the s.d.
Immunoblotting
Cells were harvested and lysed in 1 Â lysis buffer (Cell Signaling Technology, Danvers, MA, USA), followed by resolution on gradient gels (Life Technologies, Grand Island, NY, USA), transferred to nitrocellulose (Bio-Rad, Hercules, CA, USA) and probed with the indicated antibody. Primary pan-anti-CD44 and anti-b-catenin antibodies were from Cell Signaling Technology, and anti-b-actin was from Sigma-Aldrich. Densitometric quantitation was obtained using ImageJ software (National Institutes of Health; http://rsbweb.nih.gov/ij/) and normalized to b-actin, and either vehicle-treated or wild-type (wt) controls, which were arbitrarily set to 1.
Real-time PCR
Total RNA was isolated using Trizol (Life Technologies), and cDNA was synthesized using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR was performed using the TaqMan Gene Expression Master Mix and the b-catenin (6-carboxyfluorescein (FAM)), CD44 (FAM) and glyceraldehyde 3-phosphate dehydrogenase (VIC) TaqMan Gene Expression Assays as multiplexed, triplicate samples on a StepOnePlus PCR System (Applied Biosystems). Relative quantification was done using the comparative C T method after normalization to the internal glyceraldehyde 3-phosphate dehydrogenase control, where all samples were then normalized to wt or vehicle controls.
Fluorescence-activated cell sorting
Cell suspensions were stained with either Alexa Fluor 488-conjugated anti-CD44 antibody (Cell Signaling Technology) or an isotype matched control (mouse IgG2a; R&D Systems, Minneapolis, MN, USA), processed on a BD Biosciences FACSCanto II flow cytometer (San Jose, CA, USA) and analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). Quantification of CD44 levels was carried out by normalizing the mean fluorescent intensity to that of the isotype control, and then to wt or vehicle controls. Representative figures are shown from triplicate experiments and identified as the mean±s.d. For CD44 fractionation, lenalidomide-sensitive wt cells were stained with the above-described CD44 antibody and collected into CD44-high and CD44-low fractions on a BD Biosciences FACSAria III cell sorter. For apoptosis assays, cells were stained with Pacific Blue-conjugated annexin V antibody and To-Pro-3 (both from Life Technologies). Cell cycle analysis was performed by fixing cells and staining with propidium iodide (Life Technologies) as per the manufacturer's instructions.
Cell adhesion assays HS5-GFP cells were allowed to attach overnight, and myeloma cells prestained with 10 mM Calcein Blue AM (Life Technologies) were added to stromal cells. Unattached cells were removed, followed by limited trypsin digestion and scraping to remove the HS5-GFP and myeloma cells. Samples were analyzed on a FACSCanto II flow cytometer, and the percentage of events that were GFP À /Calcein Blue AM þ was determined. The relative percent adhered was calculated by: ((cell number attached fraction)/(cell number attached fraction þ cell number unattached fraction))*100, followed by normalization to wt or vehicle controls. To perform assays in HA-coated plates, 100 mg/ml (or the indicated concentration) of rooster comb HA (Sigma-Aldrich) was added to polystyrene plates, which were incubated overnight and then blocked with heat-denatured bovine serum albumin. Myeloma cells were allowed to adhere followed by gentle washing. Attached cells were resuspended in media and analyzed for relative adhesion with the WST-1 reagent (Roche Applied Science, Indianapolis, IN, USA). All cell adhesion assays were performed in triplicate, and data are presented as the mean ± s.d.
CD44 knockdown
Lentiviral-based shRNAs targeted to CD44 (Addgene, Cambridge, MA, USA), or a non-specific scrambled control, were transfected with packaging vectors using Lipofectamine (Life Technologies) into HEK293 cells. Concentrated supernatant was used to transduce lenalidomide-sensitive or -resistant cells, which were selected with puromycin (Sigma-Aldrich).
Xenograft modeling
Lenalidomide-resistant U266/R10R cells (7.5 Â 10 6 /mouse) were subcutaneously xenografted into 6-week-old non-obese diabetic severe combined immunodeficiency mice (NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ; Jackson Laboratories, Bar Harbor, ME, USA) with MatriGel (BD Biosciences) under a protocol approved by the Institutional Animal Care and Use Facility. Treatments were administered by Intraperitoneal injection using peanut oil as a carrier thrice weekly, starting on day 7 post implantation. Tumors were monitored by caliper measurement, and tumor volume was determined using the equation
Xenograft statistical analysis An unstructured covariance structure was used to account for inter-mouse variability and the longitudinal nature of the data. An interaction between treatment and time was assessed to test the heterogeneity of slopes, that is, the tumor growth rate. CONTRAST statement in PROC MIXED procedure in SAS was used to compare the tumor growth rates between each pair of treatment groups. The tumor volume was log-transformed to satisfy the normality assumption of the models. Pair-wise differences between the combination group (lenalidomide þ ATRA) vs ATRA alone, combination vs lenalidomide, combination vs control, lenalidomide vs control and ATRA vs control were examined using ESTIMATE statement in PROC MIXED for each time point. Statistically significant determinations were made by calculation of the probability of w 2 -test. Cooperative effects of the combination of lenalidomide and ATRA are assessed using a Bayesian bootstrap procedure. We calculated Pr(min(m L , m A )4m C |data) (that is, the posterior probability that the minimum of the two posterior mean tumor volumes for lenalidomide alone, m L , or ATRA alone, m A , was greater than the mean posterior tumor volume for the combination m C ). Cooperative effects are shown if this posterior probability is large. The cooperative effects of the combination on tumor volume were assessed at each time separately. SAS version 9.1 and S-Plus version 8.0 were used to carry out the computations for all analyses.
RESULTS
Lenalidomide-resistant cells overexpress CD44
Previous findings from our group identified activation of the Wnt/b-catenin pathway as being associated with lenalidomide resistance in a dose-and time-dependent fashion in our novel lenalidomide-resistant model cell lines compared with vehicletreated controls. Blocking the CD44/HA interaction induces cytotoxicity Given the enhanced adhesive properties of lenalidomide-resistant cells associated with increased CD44 expression, we next considered the possibility that interfering with the CD44/HA interaction could be of therapeutic benefit. This was first tested by adding exogenous HA to saturate myeloma cell-surface CD44 and prevent its binding to HA-coated plates. When lenalidomide-resistant ANBL-6/R10R and U266/R10R cells were incubated with free HA, mild anti-proliferative effects were seen (Figure 3a) , especially in the U266 model, which, notably, has even higher CD44 expression than ANBL-6 cells ( Figure 1c ). Lenalidomide alone without HA showed no activity against the resistant cells, as expected, but when lenalidomide was added in the presence of pretreatment with HA, lenalidomide sensitivity was restored, and substantial reductions in cell proliferation were seen. Drug-naive ANBL-6wt and U266wt cells were then exposed to lenalidomide with or without HA (Figure 3b ). Qualitatively similar findings were obtained, and the combination showed enhanced effects, except that lenalidomide alone was sufficient to reduce cellular viability, again as expected. To examine the mechanism behind this interaction, U266/R10R cells incubated with vehicle, lenalidomide and HA, or HA and then lenalidomide, were analyzed by staining for annexin V and with To-Pro-3 ( Figure 3c ). Lenalidomide alone cells were subjected to quantitative PCR, and CD44 mRNA content was analyzed using the comparative C T method and normalized to glyceraldehyde 3-phosphate dehydrogenase internal control. CD44 expression in drug-naive wt cells was arbitrarily set at 1.0, and representative data are shown from one of three independent experiments along with the s.d. (b) CD44 protein levels were evaluated in drugnaive and lenalidomide-resistant cells by western blotting. Densitometric quantitation of the total CD44 levels is shown from one of two independent experiments, and was first normalized to the b-actin loading control, and then compared with wt levels, which were arbitrarily set at 1.0. (c) Lenalidomide-sensitive (dotted line) and -resistant (solid line) cells were subjected to FACS analysis to determine the levels of cellsurface CD44 using an Alexa Fluor 488-conjugated CD44 antibody. On the left, a representative FACS profile is shown from one of three independent experiments, each of which collected 20 000 events. Quantitative analysis of the mean fluorescent intensity of these data was then used to calculate the fold increase of surface CD44 levels in the lenalidomide-resistant cells following normalization to the isotype control, which is displayed on the right.
did not substantially alter the proportion of annexin V þ cells compared with the vehicle, where 14.5% of cells were apoptotic. In the presence of HA, 37.1% of cells were annexin V þ , whereas HA followed by lenalidomide increased this to 50.9%, indicating that type I programmed cell death was contributing to the enhanced anti-proliferative effects of HA and lenalidomide. Because HA would not be relevant to the clinic, we next evaluated the efficacy of a humanized monoclonal anti-CD44 antibody (RO5429083). As a single agent, RO5429083 exerted a modest anti-proliferative effect, with an approximately 20% reduction in viability against both ANBL-6/R10R and U266/R10R cells (Figure 3d) . Notably, although lenalidomide alone was ineffective, RO5429083 with lenalidomide was more active than the antibody alone in the absence of any effector cells to mediate antibody-dependent cellular cytotoxicity. Comparable findings were seen in the drug-naive ANBL-6 and U266 cells (Figure 3e ), except that both lenalidomide and RO5429083 were active as single agents. Finally, the lenalidomide/RO5429083 combination activated apoptosis in virtually all of the U266/R10R cells (Figure 3f ).
CD44 suppression sensitizes myeloma cells to lenalidomide
In that HA may mediate effects through mechanisms other than targeting CD44, it was of interest to verify that CD44 was itself involved in lenalidomide resistance. We therefore generated ANBL-6 and U266 cell lines in which both the wt and R10R cells were infected with lentiviral vectors expressing a scrambled sequence shRNA, or one targeting and suppressing CD44 (Supplementary Figure 1) . These cells were then seeded onto HA-coated plates, exposed to lenalidomide and evaluated for viability. Lenalidomide-resistant ANBL-6/R10R (Figure 4a , left panel) and U266/R10R (Figure 4a , right panel) were markedly sensitized to lenalidomide by CD44 knockdown compared with the scrambled control. In contrast, relatively modest effects were seen in the lenalidomide-sensitive wt cells, suggesting a lesser þ , lenalidomide-sensitive wt or lenalidomide-resistant ANBL-6 or KAS-6 cells were then added. Non-adherent cells were subsequently washed off, and the GFP À /Calcein Blue AM þ signal was measured. The percentage of adhesion was calculated as described in the 'Materials and Methods' and normalized to the adhesion of wt cells, which were arbitrarily set at 1.0. (b) Lenalidomide-sensitive and -resistant ANBL-6 and KAS-6/1 cells were evaluated for their ability to adhere to increasing concentrations of hyaluranon (HA) immobilized in culture plates, and evaluated as above. (c) Free HA or a CD44-blocking antibody were pre-incubated with the indicated myeloma cell lines, which were then allowed to adhere to BMSCs and analyzed as above. Relative adhesion was determined and compared with an isotype control, with data displayed as the mean ± s.d. All results are representative of three independent experiments. dependence on CD44 for survival. The effect of CD44 knockdown on apoptosis was then studied by FACS analysis in ANBL-6 ( Figure 4b , left panel) and U266 cells (not shown), which revealed that this maneuver enhanced the ability of lenalidomide to induce apoptosis by up to fourfold (Figure 4b, right panel) . In an attempt to show the reverse effect, we tried to overexpress the full-length CD44 (Origene-NM_000610); however, this overexpression appeared to be lethal by both transient transfection in HEK293 cells and lentiviral transduction in lenalidomide-sensitive U266 or ANBL-6 cells (data not shown). As an alternative approach, we reasoned that because the emergence of drug-resistant clones could be due to the induction of a new phenotype, or due to Figure 3 . Impact of CD44 blockade on the effectiveness of lenalidomide. (a) Utilizing immobilized HA to represent the marrow microenvironment, lenalidomide-resistant ANBL-6 and U266 cells were pre-incubated with increasing concentrations of free HA (25-100 mg/ml). They were then exposed either to vehicle or lenalidomide for 72 h, and viability was determined with the tetrazolium reagent WST-1. Data are from three independent experiments and are presented as the mean±s.d., with '*' representing statistical significance at a level of Po0.05 using the Student's paired t-test. (b) The experiment described in a was performed with lenalidomide-naive ANBL-6 and U266 cells to study the impact of CD44 blockade on the acute effects of lenalidomide. (c) FACS analysis was used to determine the proportion of apoptotic (annexin V þ ) cells in the U266 model system after the above-described experiments. (d) Again utilizing immobilized HA to represent the marrow microenvironment, lenalidomide-resistant ANBL-6 and U266 cells were pre-incubated with increasing concentrations of a humanized anti-CD44 monoclonal antibody (RO5429083). They were then exposed either to vehicle or lenalidomide for 72 h, and viability was determined with the tetrazolium reagent WST-1. Data are from three independent experiments and are presented as the mean±s.d., with '*' representing statistical significance at a level of Po0.05 using the Student's paired t-test. (e) The experiment described in d was performed with lenalidomide-naive ANBL-6 and U266 cells to study the impact of CD44 blockade on the acute effects of lenalidomide. (f ) FACS analysis was used to determine the proportion of apoptotic (annexin V þ ) cells in the U266 model system after the above-described experiments.
the selection of a preexisting subpopulation, we fractionated ANBL-6wt and MM1.Swt cells into high CD44-and low CD44-expressing populations (Supplementary Figure 2) . Following treatment with lenalidomide, viability assays showed a significant disparity between these populations, with the CD44-low cells demonstrating greater lenalidomide sensitivity compared with the CD44-high population in the presence of immobilized HA (Figure 4c ).
Clinically relevant approaches to re-sensitize to lenalidomide Lenalidomide resistance is an emerging clinical problem, and we therefore wanted to validate novel approaches that could recapture lenalidomide sensitivity. Signaling through IL-6 is known to regulate the cell-surface expression of CD44 in myeloma cells. 14 We therefore reasoned that IL-6 blockade could undermine CD44-mediated lenalidomide resistance, and used siltuximab, a neutralizing anti-IL-6 antibody that has shown pre-clinical activity against myeloma.
15-17 IL-6-dependent, lenalidomide-resistant ANBL-6/R10R and KAS-6/R10R cells were therefore exposed to siltuximab or lenalidomide alone, as well as in combination (Supplementary Figure 3A) . As expected, lenalidomide alone showed no activity, and although siltuximab did reduce viability, this was enhanced with the combination, consistent with resensitization to lenalidomide. Moreover, in drug-naive cells (Supplementary Figure 3B) , a greater reduction in viability was seen with the combination, suggesting a chemosensitizing effect. In the small-molecule category, we evaluated FH535 18 , a novel b-catenin/T-cell factor antagonist. The combination of lenalidomide and FH535 significantly reduced the viability of KAS-6/R10R and U266/R10R cells (Supplementary Figure 4A) even under conditions when either agent alone showed minimal activity, and additive or greater activity was seen in drug-naive models as well (Supplementary Figure 4B) .
As neither siltuximab nor FH535 is available outside of clinical trials, we next evaluated ATRA, which alters the subcellular distribution of b-catenin, 19 induces its ubiquitin-dependent degradation, 20 inactivates b-catenin-dependent signaling 21 and reduces CD44 expression. 21, 22 ATRA reduced basal b-catenin-dependent lymphoid enhancer factor/T-cell factor promoter activity in Figure 4 . CD44 expression level and lenalidomide sensitivity. (a) Lenalidomide-sensitive and -resistant ANBL-6 and U266 cells were infected with lentiviral particles containing shRNA constructs targeted to a non-specific scrambled sequence or CD44. Stable clones with verified knockdown propagated on HA-coated plates were then exposed to lenalidomide, and viability was analyzed utilizing the WST-1 assay. Mean viability values are provided from three independent experiments ± s.d., and the Student's paired t-test was used to determine statistical significance, where '**' denotes Po0.01. (b) FACS analysis of these ANBL-6 and U266 models was then performed to examine the proportion of apoptotic (annexin V þ ) cells. The fold increase in the apoptotic cell population is shown on the right and was obtained by normalizing the % apoptosis for scrambled controls to 1.0. (c) Lenalidomide-sensitive ANBL-6 and MM1.S cells were sorted into CD44-high and CD44-low populations and treated with lenalidomide at the indicated concentrations for 72 h. Cellular viability measurements were then performed using the WST-1 assay, and all data points were normalized to the vehicle control, which was arbitrarily set at 100%. Mean viability values are provided from three independent experiments ± s.d., and the Student's paired t-test was used to determine statistical significance, where '*' denotes Po0.05 and '**' denotes Po0.01. Figure 5A) and reversed the acute, lenalidomide-stimulated activation of lymphoid enhancer factor/ T-cell factor in a time-and concentration-dependent manner (Supplementary Figure 5B) . As a single agent, ATRA had minimal effects against lenalidomide-resistant KAS-6/1 and U266 cells (Figure 5a , left panel), but this increased substantially in the presence of lenalidomide, which by itself was inactive. In drugnaive cells, ATRA showed greater activity, and again enhanced the efficacy of lenalidomide (Figure 5a, right panel) . Lenalidomide also increased by more than twofold the percentage of cells that stained for the early apoptotic marker annexin V when used in combination with ATRA in U266/R10R cells (Figure 5b ). Analysis of cell cycle effects indicated that ATRA or lenalidomide alone induced a G 1 arrest, but this was greatly enhanced when the two drugs were combined in either lenalidomide-sensitive or lenalidomide-resistant KAS-6/1 cells (Figure 5c ). Molecular effects of ATRA To further examine the molecular mechanisms by which ATRA was working, we studied its impact on b-catenin transcription using quantitative PCR. ANBL-6 cells exposed to ATRA showed a dramatic decrease in b-catenin mRNA levels, and although lenalidomide increased these, ATRA suppressed this effect (Figure 6a, left panel) . ATRA also reduced b-catenin protein levels in lenalidomide-resistant KAS-6/1 cells (Figure 6a, middle panel) and impeded the ability of lenalidomide to cause b-catenin accumulation (Figure 6a, right panel) . Our earlier data suggested that CD44 was a mediator of the resistant phenotype induced by b-catenin activation, and ATRA was found to reduce CD44 expression in both drug-naive and lenalidomide-resistant cells at baseline (Figure 6b ATRA overcomes lenalidomide resistance in vivo and in primary samples It was also of interest to validate the ability of ATRA to enhance the cytotoxic effects of lenalidomide in vivo, and we therefore used immunodeficient mice and U266/R10R cells to develop a lenalidomide-resistant xenograft model. Seven days after inoculation, these mice were randomized to treatment with intraperitoneal injections of vehicle, lenalidomide, ATRA or lenalidomide with ATRA. Although lenalidomide did not induce tumor growth delay, ATRA alone did show some activity in this setting (Figure 7a) . Notably, the lenalidomide/ATRA combination significantly reduced tumor growth compared with either agent alone (Figure 7b) , and also showed a trend toward prolonging survival (Figure 7c ). Additional statistical analysis suggested that these two drugs show a cooperative effect when used together, which was seen by day 16 and peaked at day 21 (Supplementary Figure 6) .
KAS-6wt cells (Supplementary
We also wanted to study the effects of ATRA and lenalidomide in primary samples, and therefore first evaluated cell-surface levels of CD44 by FACS. In samples collected from patients who had received prior lenalidomide, including many who were clinically lenalidomide refractory, we found a significantly increased CD44 surface expression compared with samples from lenalidomidenaive patients (Figure 7c ). Finally, we studied the effects of lenalidomide and ATRA on primary CD138
þ cells from patients with clinically refractory/relapsed disease after at least one prior lenalidomide-containing regimen. All seven primary samples showed a reduction in viability of not 430% with lenalidomide alone, whereas some (MM2, MM5 and MM7) exhibited a negligible response. Most of the samples showed some response to ATRA, but in all of the samples, the ATRA/lenalidomide combination was superior at reducing cellular viability. Together, these data support the hypothesis that lenalidomide resistance associated with Wnt/b-catenin activation is at least in part mediated by CD44 and CAM-DR, and validate approaches that target Wnt/b-catenin and/or CD44 as rational maneuvers to overcome lenalidomide resistance.
DISCUSSION
The incorporation of novel drugs such as proteasome inhibitors and immunomodulatory agents into our chemotherapeutic armamentarium against multiple myeloma has dramatically improved the outcomes of patients afflicted with this disease. 23, 24 Lenalidomide is the key member of the latter drug class, partly because of a more favorable toxicity profile and enhanced activity. 25 Initially approved for myeloma as an approach to combat relapsed and relapsed/refractory disease in combination with high-dose dexamethasone, 26, 27 lenalidomide, which is also active by itself, 28 is now being used in many combinations in this setting, such as with bortezomib and dexamethasone. 28 Moreover, lenalidomide is now a standard of care with low-dose dexamethasone, 29 bortezomib and dexamethasone, 30 Figure 6. Molecular correlates of ATRA action in lenalidomide-resistant myeloma. (a) Lenalidomide-sensitive ANBL-6 cells were exposed to either vehicle, lenalidomide, ATRA or the combination for 72 h, and b-catenin mRNA levels were determined by quantitative PCR using the comparative C T method. Values were normalized to glyceraldehyde 3-phosphate dehydrogenase as an internal control, and the vehicle condition was arbitrarily set at 1.0 (left panel). The influence of ATRA on b-catenin protein levels was verified by western blotting in KAS-6 lenalidomide-resistant cells treated with ATRA alone (middle panel) and in ANBL-6 drug-naive cells exposed to vehicle, lenalidomide (L), ATRA (A) or both (L þ A). b-actin is displayed as a loading control, and densitometry was performed to quantify b-catenin levels, which were normalized to vehicle controls arbitrarily set to 1.0. Representative blots from one of three experiments are shown. (b) Lenalidomide-sensitive and -resistant U266 cells were exposed to vehicle, lenalidomide, ATRA or the combination for 72 h. Western blotting was then performed to determine the total cellular content of CD44 with b-actin serving as a loading control, whereas quantitation was performed as described for a.
(c) Cell-surface levels of CD44 were determined by FACS utilizing an Alexa Fluor 488-conjugated anti-CD44 antibody following exposure to ATRA at the indicated concentrations for 3, 6, 24 or 48 h. All values were normalized to the respective vehicle control, which was arbitrarily set at 1.0, and are represented as relative CD44 cell-surface levels from one of two representative and independent experiments.
or melphalan and prednisone 31 for newly diagnosed, symptomatic disease. Finally, lenalidomide is increasingly used as a single agent in maintenance therapy for transplant-ineligible patients, 31 and in patients who have previously undergone stem cell transplantation. 32, 33 However, long-term follow-up of patients continuously treated with lenalidomide has not revealed a plateau in the progression-free or overall survival curves, [31] [32] [33] [34] and the vast majority suffer disease progression, indicating the outgrowth of drug-resistant clones. These findings indicate the importance of understanding the lenalidomide-resistant phenotype at the molecular level, so that novel strategies can be developed to overcome it, or possibly preclude its emergence altogether.
To begin to elucidate the mechanisms that contribute to lenalidomide resistance, we previously developed myeloma cell lines that were resistant to the anti-proliferative and pro-apoptotic effects of this agent. 3 After identifying activation of the Wnt/b-catenin signaling pathway, 3 we have herein demonstrated that at least one downstream transcriptional target, CD44, may be a mediator of the lenalidomide-resistant phenotype. Notably, although our results support the hypothesis that CD44 mediates the resistant phenotype in part through the protective effect of enhanced cellular adhesion, the role of downstream CD44/HA signaling is not known. We are currently exploring the role of CD44-mediated intracellular signaling in the resistant phenotype, which may include the activation of Akt, 35 a known pro-survival factor important in multiple myeloma. Also, from a mechanistic standpoint, there is an apparent paradox concerning the engagement of CD44 to HA, and the differences between downstream signaling effects with an anchorage-or immobilized-dependent effect. 36, 37 This paradox is also reflected in our data that suggest that CD44 binding to free HA acts as an antagonist 38 , especially in the presence of lenalidomide, whereas binding to immobilized HA had a protective benefit. In this context, it is clear that the role of immobilized HA, which would be prevalent in the bone marrow microenvironment, would serve to protect cells that overexpress CD44 from lenalidomide-induced cytotoxicity.
Furthermore, our findings showed a strong association between CD44 expression and prior exposure and clinical resistance to lenalidomide. It is therefore possible to advance the hypothesis that plasma cell-surface CD44 levels determined by FACS, or mRNA levels determined by gene expression profiling, or even soluble serum CD44 levels, could serve as biomarkers of lenalidomide resistance. Patients whose disease would be showing evidence of clinical lenalidomide resistance could then be evaluated to determine if CD44 was activated, and those where this was found to be the case could be selected for therapy with the lenalidomide/ATRA combination. þ plasma cells obtained from patients who were lenalidomide refractory were treated for 72 h with vehicle, lenalidomide, ATRA or the combination, and viability was then analyzed using the WST-1 assay. All values are normalized to the vehicle control, which was set at 100%, and presented as the average of triplicate measurements ± s.d.
From a clinical perspective, we have potentially identified an effective and well-tolerated active agent in ATRA to reduce the protective effects of CD44 against lenalidomide through blockade of the Wnt/b-catenin signaling pathway, in patients who display relapsed/refractory disease against lenalidomide-based regimens. Notably, although an initial study of ATRA in relapsed/refractory myeloma described hypercalcemia as a complication in three patients, 39 subsequent trials have found it to be well tolerated both alone and in combination with other agents, 40, 41 supporting the translation of this concept to the clinic.
Alternatively, it may be proposed that the lenalidomide/ATRA regimen could be started instead of single-agent lenalidomide in patients whose disease showed higher CD44 levels at baseline, or even in all patients to suppress the emergence of resistance. Another interesting finding from our studies was that even drugnaive cell lines contained a subpopulation of cells that expressed higher CD44 levels, and these were relatively resistant to lenalidomide at baseline. This raises the question of whether the development of lenalidomide resistance occurs by acquisition of a new drug-induced phenotype, or whether it is a result of selection of a preexisting clone that is already relatively resistant before exposure to drug. Recent whole-genome sequencing studies in murine myeloma models, 42 and of primary patient samples, 43 have described compelling evidence of a prominent role for competition between subclones both spontaneously and with therapeutic selection. These findings, as well as our studies showing effects of lenalidomide on the Wnt/b-catenin/CD44 axis, suggest that both drug-induced effects on the cell population as a whole, as well as selection of specific clones, probably contribute to the drug-resistant phenotype.
Our data strongly support a role for signaling through the Wnt/b-catenin axis in the development of lenalidomide resistance. In this study, we also showed the direct involvement of CD44/HA engagement in protection from lenalidomide-induced cytotoxicity by shRNA knockdown of CD44. Curiously, even though we knocked down CD44 in lenalidomide-sensitive cells, we did not increase their sensitivity. This observation could be due to a number of possibilities, but may be most likely due to the lower dependence of the drug-sensitive cells on CAM-DR as mediated by CD44. Another mediator of immunomodulatory drug resistance that has been identified is cereblon. Initially described in the context of myeloma as the primary target of teratogenicity for thalidomide, 44 cereblon has more recently been shown to be required for the anti-proliferative activity of immunomodulatory agents. 45, 46 Moreover, cereblon suppression was associated with resistance to lenalidomide, 45 whereas its overexpression enhanced sensitivity to pomalidomide. 46 Interestingly, in our lenalidomide-resistant ANBL-6-, KAS-6/1-and U266-derived cells, cereblon expression was relatively preserved (not shown). Moreover, manipulation of Wnt/b-catenin activity, such as with ATRA, did not enhance cereblon expression levels (not shown), indicating that this was not responsible for restoration of lenalidomide sensitivity. These data suggest the hypothesis that the Wnt/b-catenin axis and cereblon represent different mechanisms for lenalidomide resistance. However, the possibility that these are somehow linked still needs to be considered as well, and further mechanistic studies are being pursued in this area.
Patients with myeloma have benefited greatly from therapeutic approaches incorporating lenalidomide, but one cautionary note has been raised by three recent randomized studies, in which lenalidomide was given as a single agent in the maintenance setting. [31] [32] [33] All three studies showed a small increase in the risk of second primary malignancies among patients who received maintenance with lenalidomide compared with the placebo groups. These malignancies included a wide range of solid tumors, such as breast, central nervous system, colon, esophageal, gynecological, prostate, sinus, thyroid and kidney tumors, and melanoma. Hematological malignancies were seen as well, including acute myeloid leukemia, Hodgkin and non-Hodgkin lymphomas, myelodysplastic syndrome, T-cell and B-cell acute lymphoblastic leukemias and myelomonocytic leukemia. Moreover, retrospective analysis of studies in patients with relapsed and/or refractory myeloma also showed an increased risk of second primary malignancies among those treated with lenalidomide and dexamethasone. 47 Multiple influences probably contribute to the increased risk of secondary malignancies in patients with myeloma, including those due to host genetic and behavioral factors, environmental factors, and myeloma-and treatment-related factors. 48 Notably, dysregulation of Wnt/bcatenin/CD44 signaling resulting in the activation of this pathway has been linked to the pathogenesis of virtually all of these and other tumor types, as well as their progression and aggressiveness, and in the maintenance of cancer stem cells.
5, [49] [50] [51] [52] Thus, it is tempting to speculate that, if our data showing induction by lenalidomide of the Wnt/b-catenin/CD44 axis in malignant plasma cells can be reproduced in normal tissues, this may be the mechanistic link between lenalidomide and second primary malignancies. If that is indeed the case, then blockade of Wnt/b-catenin/CD44 signaling could not only enhance the activity of lenalidomide and improve the outcomes of patients with myeloma but also reduce the risk of second primary tumors.
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